Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotype-guided imatinib dosing in pulmonary arterial hypertension
2020-001157-48Phase 2Unknown
- Sponsor
- Imperial College London
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of imatinib in Plexogenic Pulmonary Arteriopathy, Heritable Pulmonary Arterial Hypertension (HPAH) and pulmonary arterial hypertension (PAH), sponsored by Imperial College London. Primary endpoint: Six-minute walk test change. Status: unknown.
02
Drugs
03
Conditions
Plexogenic Pulmonary ArteriopathyHeritable Pulmonary Arterial Hypertension (HPAH)pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2020-001157-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001157-48.